Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review

Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review

Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced driver-negative non-small cell lung cancer (NSCLC). However, targeted therapy remains the preferred treatment for advanced driver-positive NSCLC, including cases with epidermal growth factor receptor...

Full description

Saved in:
Bibliographic Details
Main Authors: Yi Dong, Liaqat Khan, Yi Yao
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Journal of the National Cancer Center
Subjects:
Epidermal growth factor receptor (EGFR)
Immunological features
Immunotherapy
Mutation
Non-small cell lung cancer (NSCLC)
Online Access:http://www.sciencedirect.com/science/article/pii/S2667005424000474
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items